APA (7th ed.) Citation

GD, H., G, C., M, R., J, G., R, B., D, L., . . . K, D. (2020). Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(12), 3110. https://doi.org/10.1093/cid/ciz1213

Chicago Style (17th ed.) Citation

GD, Huhn, et al. "Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 71, no. 12 (2020): 3110. https://doi.org/10.1093/cid/ciz1213.

MLA (9th ed.) Citation

GD, Huhn, et al. "Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 71, no. 12, 2020, p. 3110, https://doi.org/10.1093/cid/ciz1213.